Neal Sondheimer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neal Sondheimer has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Ornella Zollo
Division of Biochemical Genetics, The Children's Hospital of Philadelphia Philadelphia, 19104, Pennsylvania
3 shared publications- Catherine Glatz
Division of Child Rehabilitation and Biochemical Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, United States
2 shared publications Matthew A. Deardorff
Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA
2 shared publicationsAbba M. Krieger
Department of Statistics, The University of Pennsylvania, Philadelphia, PA, USA and
1 shared publicationAlden M. Doyle
Department of Internal Medicine Drexel University College of Medicine Philadelphia, PA
1 shared publicationAtrish Bagchi
Department of Biochemistry and Biophysics and Graduate Group in Biochemistry and Molecular Biophysics, The University of Pennsylvania Philadelphia, 19104, Pennsylvania
1 shared publication
Latest Publications
- Open Access
- 4 June 2015
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 3 (5) , 452-458
EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features
The epidermal growth factor receptor (EGFR) is part of a large family of receptors required for communicating extracellular signals through internal tyrosine kinases. Epidermal growth factor (EGF) signaling is required for tissue development, whereas constitutive activation of this signaling pathway is associated with oncogenic transformation. We identified homozygous c.1283G>A (p.Gly428Asp) mutations in the extracellular domain of EGFR in two siblings. The children were born prematurely, had abnormalities in skin and hair, suffered multisystem organ failure, and died in the neonatal period from intestinal perforation. EGF failed to induce mutated receptor phosphorylation in patient‐derived fibroblasts and activation of downstream targets was suppressed. The heterologously expressed extracellular domain was impaired in stability and the binding of EGF. Cells from the affected patient undergo early senescence with accelerated expression of β‐galactosidase and shortened telomeres at all passages when compared to controls. A comparison of homozygous inherited regions from a separate report of a patient from the same ethnic background and EGFR genotype confirms the pathogenicity of EGFR mutations in congenital disease.
- 4 June 2015
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 3 (5) , 452-458
Open AccessEGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features
The epidermal growth factor receptor (EGFR) is part of a large family of receptors required for communicating extracellular signals through internal tyrosine kinases. Epidermal growth factor (EGF) signaling is required for tissue development, whereas constitutive activation of this signaling pathway is associated with oncogenic transformation. We identified homozygous c.1283G>A (p.Gly428Asp) mutations in the extracellular domain of EGFR in two siblings. The children were born prematurely, had abnormalities in skin and hair, suffered multisystem organ failure, and died in the neonatal period from intestinal perforation. EGF failed to induce mutated receptor phosphorylation in patient‐derived fibroblasts and activation of downstream targets was suppressed. The heterologously expressed extracellular domain was impaired in stability and the binding of EGF. Cells from the affected patient undergo early senescence with accelerated expression of β‐galactosidase and shortened telomeres at all passages when compared to controls. A comparison of homozygous inherited regions from a separate report of a patient from the same ethnic background and EGFR genotype confirms the pathogenicity of EGFR mutations in congenital disease.
- 15 April 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 97 (7) , e42-e44
Kidney Transplantation From a Deceased Donor With Metachromatic Leukodystrophy
- 15 April 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 97 (7) , e42-e44
Kidney Transplantation From a Deceased Donor With Metachromatic Leukodystrophy
- 1 July 2013
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 59 (7) , 1011-1013
Newborn Screening by Sequence and the Road Ahead
- 1 July 2013
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 59 (7) , 1011-1013
Newborn Screening by Sequence and the Road Ahead
- 18 May 2013
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 110 (1-2) , 102-105
Improving surveillance for hyperammonemia in the newborn
- 18 May 2013
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 110 (1-2) , 102-105
Improving surveillance for hyperammonemia in the newborn
- 8 November 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (3) , 515-519
Mitochondrial tRNAPhe mutation as a cause of end-stage renal disease in childhood
Background We identified a mitochondrial tRNA mutation (m.586 G > A) in a patient with renal failure and symptoms consistent with a mitochondrial cytopathy. This mutation was of unclear significance due to the absence of consistent reports of linkage to specific disease phenotypes and any data pertaining to its effects on mitochondrial function. Case-Diagnosis/Treatment A 16-month-old girl with failure-to-thrive, developmental regression, persistent lactic acidosis, hypotonia, gastrointestinal dysmotility, adrenal insufficiency, and hematologic abnormalities developed hypertension and renal impairment with chronic tubulointerstitial fibrosis, progressing to renal failure with the need for peritoneal dialysis. Evaluation of her muscle and blood led to the identification of a mutation of the mitochondrial tRNA for phenylalanine, m.586 G > A. Conclusions The m.586 G > A mutation is pathogenic and a cause of end-stage renal disease in childhood. The mutation interferes with the stability of tRNAPhe and affects the translation of mitochondrial proteins and the stability of the electron transport chain.
- 8 November 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (3) , 515-519
Mitochondrial tRNAPhe mutation as a cause of end-stage renal disease in childhood
Background We identified a mitochondrial tRNA mutation (m.586 G > A) in a patient with renal failure and symptoms consistent with a mitochondrial cytopathy. This mutation was of unclear significance due to the absence of consistent reports of linkage to specific disease phenotypes and any data pertaining to its effects on mitochondrial function. Case-Diagnosis/Treatment A 16-month-old girl with failure-to-thrive, developmental regression, persistent lactic acidosis, hypotonia, gastrointestinal dysmotility, adrenal insufficiency, and hematologic abnormalities developed hypertension and renal impairment with chronic tubulointerstitial fibrosis, progressing to renal failure with the need for peritoneal dialysis. Evaluation of her muscle and blood led to the identification of a mutation of the mitochondrial tRNA for phenylalanine, m.586 G > A. Conclusions The m.586 G > A mutation is pathogenic and a cause of end-stage renal disease in childhood. The mutation interferes with the stability of tRNAPhe and affects the translation of mitochondrial proteins and the stability of the electron transport chain.
- 30 September 2012
- Published by Elsevier in Mitochondrion
- Vol. 12 (5) , 553-554
Spontaneous elimination of mitochondrial mutations during the induction of pluripotency
- 30 September 2012
- Published by Elsevier in Mitochondrion
- Vol. 12 (5) , 553-554
Spontaneous elimination of mitochondrial mutations during the induction of pluripotency
- 27 March 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (17) , 6508-6512
Transcriptional requirements of the distal heavy-strand promoter of mtDNA
The heavy strand of mtDNA contains two promoters with non-overlapping functions. The role of the minor heavy-strand promoter (HSP2) is controversial, because the promoter has been difficult to activate in an in vitro system. We have isolated HSP2 by excluding its interaction with the more powerful HSP1 promoter, and we find that it is transcribed efficiently by recombinant mtRNA polymerase and mitochondrial transcription factor B2. The mitochondrial transcription factor A is not required for initiation, but it has the ability to alternatively activate and repress the HSP2 transcriptional unit depending on the ratio between mitochondrial transcription factor A and other transcription factors. The positioning of transcriptional initiation agrees with our current understanding of HSP2 activity in vivo. Serial deletion of HSP2 shows that only proximal sequences are required. Several mutations, including the disruption of a polycytosine track upstream of the HSP2 initiation site, influence transcriptional activity. Transcription from HSP2 is also observed when HeLa cell mitochondrial extract is used as the source of mitochondrial polymerase, and this transcription is maintained when HSP2 is provided in proper spacing and context to the HSP1 promoter. Studies of the linked heavy-strand promoters show that they are differentially regulated by ATP dosage. We conclude that HSP2 is transcribed and has features that allow it to regulate mitochondrial mRNA synthesis.
- 27 March 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (17) , 6508-6512
Transcriptional requirements of the distal heavy-strand promoter of mtDNA
The heavy strand of mtDNA contains two promoters with non-overlapping functions. The role of the minor heavy-strand promoter (HSP2) is controversial, because the promoter has been difficult to activate in an in vitro system. We have isolated HSP2 by excluding its interaction with the more powerful HSP1 promoter, and we find that it is transcribed efficiently by recombinant mtRNA polymerase and mitochondrial transcription factor B2. The mitochondrial transcription factor A is not required for initiation, but it has the ability to alternatively activate and repress the HSP2 transcriptional unit depending on the ratio between mitochondrial transcription factor A and other transcription factors. The positioning of transcriptional initiation agrees with our current understanding of HSP2 activity in vivo. Serial deletion of HSP2 shows that only proximal sequences are required. Several mutations, including the disruption of a polycytosine track upstream of the HSP2 initiation site, influence transcriptional activity. Transcription from HSP2 is also observed when HeLa cell mitochondrial extract is used as the source of mitochondrial polymerase, and this transcription is maintained when HSP2 is provided in proper spacing and context to the HSP1 promoter. Studies of the linked heavy-strand promoters show that they are differentially regulated by ATP dosage. We conclude that HSP2 is transcribed and has features that allow it to regulate mitochondrial mRNA synthesis.
- 1 July 2011
- Published by Elsevier in Mitochondrion
- Vol. 11 (4) , 615-619
Mutation in the mitochondrial tRNAVal causes mitochondrial encephalopathy, lactic acidosis and stroke-like episodes
- 1 July 2011
- Published by Elsevier in Mitochondrion
- Vol. 11 (4) , 615-619
Mutation in the mitochondrial tRNAVal causes mitochondrial encephalopathy, lactic acidosis and stroke-like episodes
- Open Access
- 4 February 2011
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 20 (8) , 1653-1659
Neutral mitochondrial heteroplasmy and the influence of aging
The development and maintenance of mitochondrial heteroplasmy has important consequences for both health and heredity. Previous studies using pathogenic mutations have shown considerable variability between maternally related individuals and studies of several D-loop polymorphisms have suggested a relationship between heteroplasmy and somatic aging. To broadly explore the variation of human heteroplasmy and to clarify the dynamics of somatic heteroplasmy over the course of lifespan, we analyzed mitochondrial sequence variation across a range of ages. We utilized array-generated single-nucleotide polymorphism data that were well correlated with independent measures of heteroplasmy. Significant levels of heteroplasmy were identified at 0.24% of sites evaluated. By examining mother–child pairs, we found that heteroplasmy was inherited (30%) but could occur de novo in offspring or, conversely, be present in mothers but eliminated in their children (70%). Cumulatively, mitochondrial heteroplasmy across the genome increased significantly with advanced age (r = 0.224, P =8 × 10−30). Surprisingly, changes in heteroplasmy were not uniform with some sites demonstrating a loss of variation (increased homoplasmy) with aging. These data suggest that both mutation and selective pressure affect blood mitochondrial DNA sequence over the course of the human lifespan and reveal the unexpectedly dynamic nature of human heteroplasmy.
- 4 February 2011
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 20 (8) , 1653-1659
Open AccessNeutral mitochondrial heteroplasmy and the influence of aging
The development and maintenance of mitochondrial heteroplasmy has important consequences for both health and heredity. Previous studies using pathogenic mutations have shown considerable variability between maternally related individuals and studies of several D-loop polymorphisms have suggested a relationship between heteroplasmy and somatic aging. To broadly explore the variation of human heteroplasmy and to clarify the dynamics of somatic heteroplasmy over the course of lifespan, we analyzed mitochondrial sequence variation across a range of ages. We utilized array-generated single-nucleotide polymorphism data that were well correlated with independent measures of heteroplasmy. Significant levels of heteroplasmy were identified at 0.24% of sites evaluated. By examining mother–child pairs, we found that heteroplasmy was inherited (30%) but could occur de novo in offspring or, conversely, be present in mothers but eliminated in their children (70%). Cumulatively, mitochondrial heteroplasmy across the genome increased significantly with advanced age (r = 0.224, P =8 × 10−30). Surprisingly, changes in heteroplasmy were not uniform with some sites demonstrating a loss of variation (increased homoplasmy) with aging. These data suggest that both mutation and selective pressure affect blood mitochondrial DNA sequence over the course of the human lifespan and reveal the unexpectedly dynamic nature of human heteroplasmy.